A detailed history of Goldman Sachs Group Inc transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 222,687 shares of AQST stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
222,687
Previous 114,009 95.32%
Holding current value
$1.02 Million
Previous $296,000 274.32%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.4 - $5.09 $260,827 - $553,171
108,678 Added 95.32%
222,687 $1.11 Million
Q2 2024

Aug 13, 2024

SELL
$2.31 - $4.5 $952,674 - $1.86 Million
-412,413 Reduced 78.34%
114,009 $296,000
Q1 2024

May 15, 2024

BUY
$2.01 - $6.09 $996,805 - $3.02 Million
495,923 Added 1626.03%
526,422 $2.24 Million
Q4 2023

Feb 13, 2024

BUY
$1.29 - $2.47 $39,343 - $75,332
30,499 New
30,499 $61,000
Q2 2023

May 14, 2024

BUY
$1.06 - $2.49 $31,211 - $73,318
29,445 Added 106.28%
57,149 $94,000
Q2 2023

Aug 14, 2023

BUY
$1.06 - $2.49 $60,577 - $142,301
57,149 New
57,149 $94,000
Q3 2022

May 14, 2024

BUY
$0.63 - $1.73 $8,533 - $23,432
13,545 Added 95.66%
27,704 $32,000
Q3 2022

Nov 10, 2022

BUY
$0.63 - $1.73 $8,533 - $23,432
13,545 Added 95.66%
27,704 $0
Q2 2022

May 14, 2024

SELL
$0.64 - $2.57 $10,457 - $41,993
-16,340 Reduced 53.58%
14,159 $9,000
Q2 2022

Aug 15, 2022

SELL
$0.64 - $2.57 $21,857 - $87,773
-34,153 Reduced 70.69%
14,159 $9,000
Q1 2022

May 16, 2022

SELL
$2.28 - $4.26 $20,508 - $38,318
-8,995 Reduced 15.7%
48,312 $126,000
Q4 2021

Feb 14, 2022

SELL
$3.69 - $6.37 $58,516 - $101,015
-15,858 Reduced 21.67%
57,307 $223,000
Q3 2021

Nov 10, 2021

BUY
$3.25 - $4.66 $237,786 - $340,948
73,165 New
73,165 $319,000

Others Institutions Holding AQST

About Aquestive Therapeutics, Inc.


  • Ticker AQST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,350,700
  • Market Cap $245M
  • Description
  • Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...
More about AQST
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.